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Abstract 
Peroxisome proliferator-activated receptor-PPARis a key regulator for 
maintaining whole-body energy balance. However, the physiological functions of PPAR in 
adipocytes have been unclarified. We examined the functions of PPAR using human 
multipotent adipose tissue-derived stem cells as a human adipocyte model. Activation of 
PPAR by GW7647, a potent PPAR agonist, increased the mRNA expression levels of 
adipocyte differentiation marker genes such as PPAR, adipocyte-specific fatty acid-binding 
protein, and lipoprotein lipase and increased both GPDH activity and insulin-dependent 
glucose uptake level. The findings indicate that PPAR activation stimulates adipocyte 
differentiation. However, lipid accumulation was not changed, which is usually observed 
when PPAR is activated. On the other hand, PPAR activation by GW7647 treatment 
induced the mRNA expression of fatty acid oxidation-related genes such as CPT-1B and AOX 
in a PPAR-dependent manner. Moreover, PPAR activation increased the production of CO2 
and acid soluble metabolites, which are products of fatty acid oxidation, and increased oxygen 
consumption rate in human adipocytes. The data indicate that activation of PPAR stimulates 
both adipocyte differentiation and fatty acid oxidation in human adipocytes, suggesting that 
PPAR agonists could improve insulin resistance without lipid accumulation in adipocytes. 
The expected effects of PPAR activation are very valuable for managing diabetic conditions 
accompanied by obesity, because PPAR agonists, usually used as antidiabetic drugs, induce 
excessive lipid accumulation in adipocytes in addition to improvement of insulin resistance. 
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1. Introduction 
Metabolic syndrome in an increasing number of people is a serious problem in many 
countries. Although many factors are involved in the development of metabolic syndrome, a 
critical factor is obesity companied by adipose tissue hypertrophy [1]. Thus, prevention and 
improvement of obesity is indispensable for treatments of metabolic syndrome. Obesity is due 
to adipocyte hyperplasia and hypertrophy caused by intake of excess energy. Therefore, it is 
important for the prevention and improvement of obesity to maintain an adequate balance 
between energy accumulation and consumption. 
Energy accumulation is regulated by peroxisome proliferator-activated receptor- 
(PPAR) in adipose tissues [2]. PPAR activation induces lipid-accumulation-related genes, 
such as fatty acid synthase (FAS), lipoprotein lipase (LPL), and fatty acid transport protein-1 
(FATP1), and promotes adipocyte differentiation [3]. As a result, the number of adipocytes 
increases in adipose tissues. Thus, a long duration of PPAR activation causes severe obesity 
and insulin resistance [4]. However, because adipocyte differentiation induced by PPAR 
activation increases the number of insulin-sensitive adipocytes, short-term or midterm PPAR 
activation improves insulin resistance [5]. Indeed, thiazolidinediones (TZDs), potent PPAR 
agonists, have been widely used as antidiabetic drugs. On the other hand, energy consumption 
is regulated by PPAR, another PPAR isoform, in the liver and skeletal muscle [6]. PPAR 
activation upregulates fatty acid oxidation-related genes including acyl-CoA synthase (ACS), 
acyl-CoA oxidase (AOX), and carnitine palmitoyl transferase (CPT) so that fatty acid 
oxidation is enhanced in both mitochondria and peroxisomes [6]. Because PPAR activation 
decreases hepatic and circulating lipid amounts, fibrates, and synthetic PPAR agonists, 
improve fatty liver and hyperlipidemia. Therefore, both PPAR isoforms serve as key 
regulators for the maintenance of whole-body energy balance, although they have opposite 
functions in energy metabolism. 
Recently, several reports have shown the involvement of PPAR in adipocyte functions 
[7,8]. However, the physiological functions of PPAR in adipocytes have not been elucidated 
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yet. Here, we examined the effects of PPAR activation on adipocyte differentiation to 
elucidate PPAR-associated regulation of energy balance between accumulation and 
consumption in adipocytes. 
 
 
2. Materials and Methods 
2.1. Chemicals and cell culture 
GW7647, a PPAR agonist, was purchased from Sigma (MO, USA) and dissolved in 
DMSO as a stock solution. All the other chemicals used were from Sigma or Nacalai Tesque 
(Kyoto, Japan) and guaranteed to be of reagent or tissue-culture grade. 
Human multipotent adipose tissue-derived stem cells established by Vernochet et al. [9] 
were used as a human adipocyte model. The cells were cultured in accordance with a protocol 
previously described [10]. Human adipocytes were maintained in a maintenance medium 
(10% FBS and 10 mg/ml penicillin/streptomycin in DMEM) at 37 °C in 5% CO2/95% air 
under a humidified condition. For white adipocyte differentiation, cells were seeded at a high 
density (25,000 cells/cm
2
). Two days after reaching confluence, the cells were incubated in 
differentiation medium (DM), which was DMEM/F12 supplemented with 1 μM 
dexamethazone (DEX), 0.1 mM 1-methyl-3-isobutylxanthine (IBMX), 5 μg/ml insulin, and 
500 nM pioglitazone. Three days after the treatment, the cell culture medium was changed to 
post-DM, which was DMEM/F-12 medium supplemented with 5 μg/ml insulin and 500 nM 
pioglitazone. The medium was then changed with a fresh one every 2 days until day 12. Cells 
were treated with the indicated concentration of GW7647 throughout experimental period 
(from day 0 to day 12). Cells cultured on 6- or 12-well tissue culture plates were prepared for 
biochemical assays. 







H]-labeled 2DG) was measured using human differentiated 
adipocytes on 24-well plates as previously described [11]. Briefly, 12 days after 
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differentiation induction in the presence or absence of GW7647, human adipocytes were 
incubated in DMEM/F-12 for 5 h. After washing with HKR buffer (containing 140 mM NaCl, 
5 mM KCl, 1 mM CaCl2, 2.5 mM MgSO4, and 20 mM HEPES; pH 7.4), the cells were then 
incubated with 0.5 mL of HKR buffer containing 1% FA-free BSA at 37°C for 20 min in the 
presence or absence of 100 nM insulin. [
3
H]-labeled 2DG (1 μCi) (American Radiolabeled 
Chemicals, MO, USA) was added to each well, followed by incubation for 10 min. The cells 
were washed with cold PBS and solubilized in 0.1 N NaOH for counting the radioactivity of 
the aqueous solution in a scintillation counter (LS6500, Beckman Coulter, CA, USA). 
 
2.2. Quantitative RT-PCR analysis 
RNA samples of differentiated human adipocytes were prepared using cells cultured on 
six-well tissue culture plates 12 days after differentiation induction. Total RNA samples were 
prepared from cells cultured on six-well tissue culture plates and from mouse fat tissues using 
Sepasol Super-I (Nacalai Tesque) and an SV total RNA isolation system (Promega, WI, USA), 
respectively, in accordance with each manufacturer’s protocol as previously described [12]. 
To quantify mRNA expression, PCR analysis was performed using a fluorescence temperature 
cycler (LightCycler System: Roche Diagnostics, Mannheim, Germany), as described 
previously [13]. Primer sets were designed using a PCR primer selection program available at 
the web site of the Virtual Genomic Center from the GenBank database as follows: 
5’-TCTCTCCGTAATGGAAGACC-3’ and 5’-GTGGGGATGTCTCATAATGC-3’ for human 
PPARγ (upstream and downstream, respectively), 5’-GCATGGCCAAACCTAACATGA-3’ 
and 5’-CCTGGCCCAGTATGAAGGAAA-3’ for human adipocyte-specific fatty acid-binding 
protein (aP2), 5’-GTGGCCAAATAGCACATCCT-3’ and 
5’-CCGAAAGATCCAGAATTCCA-3’ for human lipoprotein lipase (LPL), 
5’-CTCCTTTCCTTGCTGAGGTG-3’ and 5’-TCTCGCCTGCAATCATGTAG-3’ for human 
carnitine palmitoyltransferase-1B (CPT-1B), and 5’-TGCCCAACTGTGCAATGAA-3’ and 
5’-TCGCAAGAAGGAAGGTACCAA-3’ for human uncoupling protein-1 (UCP1). All other 
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primer sets used in this study were described in our previous reports [13,14]. To compare 
mRNA expression level among samples, the copy number of each transcript was divided by 
that of 36B4 showing a constant expression level. All data on mRNA expression level are 
presented as ratio with respect to the mRNA expression level in a control in each experiment. 
 
2.3. Biochemical assays 
Cells were washed twice with PBS and collected by scraping with a cell scraper into 25 
mM Tris-HCl (pH 7.4) containing 1 mM EDTA. The cell suspension was sonicated for 5 sec 
at 40 watts with a microson ULTRASONIC CELL DISRUPTOR (Misonix Inc., NY, USA). 
After centrifugation at 12,800×g for 5 min at 4°C, the supernatants were assayed for GPDH 
activity as described previously [12]. One unit of GPDH activity is the amount causing the 
oxidation of 1 μmol of NADH per min. For Oil Red O staining, human adipocytes 12 days 
after the induction of differentiation were fixed with 10% formaldehyde/PBS and stained with 
Oil Red O solution (0.5% Oil Red O-isopropyl alcohol/H2O (3:2, v/v)) as described 
previously [15]. 
To determine intracellular TG amount, human adipocytes were washed with PBS, and 
placed immediately in lysis buffer containing 50 mM PIPES (pH 6.5) and 1% Triton X-100. 
The lysate was centrifuged at 10,000 rpm for 5 min, and supernatants were collected. TG 
content was measured enzymatically using TG E-test Wako (Wako Pure Chemicals, Osaka, 
Japan). 
 
2.4. Fatty acid oxidation measurement 
Eleven days after differentiation induction, human adipocytes were incubated in DMEM 
containing 0.2 mM palmitic acid, 2.5% FA-free BSA, 200 μM 1-carnitine, and [14C]-palmitic 
acid (1 μCi) (American Radiolabeled Chemicals) for 16 h. Fatty acid (FA) oxidation products 
were assessed as previously described [16] with modification. Briefly, the labeling medium 
was collected and centrifuged, and the supernatant was transferred to a 50 mL polypropylene 
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tube. An uncapped Eppendorf tube containing a piece of filter paper soaked in benzethonium 
hydroxide was placed inside a 50-mL tube. After the tube was sealed, 200 μL of 70% 
perchloric acid was added to the medium sample to release [
14
C]-CO2. The tube was then 
shaken at 37°C for 1 h. The saturated filter paper containing trapped [
14
C]-CO2 was assessed 
for radioactivity in a liquid scintillation counter (LS6500, Beckman Coulter). The acidified 
medium was centrifuged twice to remove particulate matter, and 200 μL of supernatant was 
assessed for the amount of [
14
C]-labeled acid soluble metabolites (ASMs), which include 
labeled ketone bodies. 
 
2.5. Statistical analysis 
The data are presented as means ± S.E.M. and statistically analyzed by one-way 
ANOVA when their variances were heterogeneous and the unpaired t-test. Differences were 




3.1. A PPAR agonist promoted adipocyte differentiation but not triglyceride accumulation in 
human adipocytes. 
To examine the effects of PPAR activation on human adipocyte differentiation, 
GW7647 (a potent PPAR agonist) was added to the medium and the cells were incubated for 
12 days (the concentrations of GW7647 used in this study showed no effect on PPAR 
activity). The addition of GW7647 increased mRNA expression levels of adipocyte 
differentiation marker genes, namely, PPAR, aP2, and LPL (Fig. 1A). The mRNA expression 
level of PPAR statistically significantly increased and those of other genes tended to increase. 
The PPAR mRNA expression level remained constant during the culture period, although the 
mRNA expression level of PPAR was 10-50-fold lower than that of PPAR (data not shown). 
The activity of GPDH, a biochemical differentiation marker, also increased following 
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treatment with GW7647 in a dose-dependent manner. The data suggest that GW7647 
treatment promotes human adipocyte differentiation. Thus, we examined insulin sensitivity 
because the promotion of adipocyte differentiation increases insulin sensitivity [5]. As shown 
in Fig. 2, GW7647 treatment increased the insulin-dependent uptake of glucose. Therefore, 
we concluded that PPAR activation promoted the differentiation of human adipocytes. 
Next, we studied the effects of PPAR activation on TG accumulation in human 
adipocytes because the promotion of adipocyte differentiation increases TG amount in 
adipocytes. Surprisingly, GW7647 treatment did not increase accumulated TG amount in 
human adipocytes (Fig. 3). This finding is inconsistent with the observation that PPAR 
activation causes adipocyte differentiation, as shown above. 
 
3.2. Activation of PPAR enhanced fatty acid oxidation in human adipocytes. 
To clarify this inconsistency, we measured the mRNA expression levels of fatty acid 
oxidation-related genes. GW7647 treatment increased the mRNA expression levels of CPT-1B 
and AOX, which are rate-limiting enzymes in mitochondria and peroxisomes, respectively 
(Fig. 4A). Interestingly, the mRNA expression level of UCP1, which is involved in energy 
consumptions, also increased. The induced expression of CPT-1B was abrogated by GW6471, 
a synthetic PPAR antagonist (Fig. 4B), indicating that the induction of this gene is 
dependent on PPAR activity. Moreover, the evaluation of CO2 and ASM releases using 
[
14
C]-palmitic acid revealed that GW7647 treatment increased the amounts of released CO2 
and ASMs, which are products of fatty acid oxidation, in human adipocytes (Figs. 4C and D). 
These findings indicated that PPAR activation increases fatty acid oxidation in human 




PPAR regulates adipocyte differentiation [17]. This regulation is mediated by the 
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induction of the mRNA expression of PPAR target genes. When an agonist binds to the 
ligand-binding domain of PPAR, a heterodimer of PPAR and RXR is recruited onto the 
PPAR-response element (PPRE) inducing mRNA expression [18]. Target genes such as aP2, 
LPL, and GLUT4 have PPRE in their own promoter regions. However, PPRE bound by 
PPAR cannot be distinguished from that bound by PPAR, although affinities to other PPAR 
isoforms might differ in each PPRE. Recently, it has been reported that synthetic PPAR 
agonists such as fenofibrate and bezafibrate induce adiponectin mRNA expression in mouse 
3T3-L1 adipocytes; adiponectin is a typical PPAR target gene in adipocytes [8]. On the other 
hand, the sequence of the PPRE of the promoter of human AOX, which is a PPAR target 
gene in hepatocytes, has been widely used in luciferase assay for all PPAR isoforms [19,20]. 
Thus, there is a possibility that each PPAR isoform can induce the mRNA expression of target 
genes known to be induced by other PPAR isoforms, although it has not yet been elucidated 
how the specificities of isoforms or tissues are manifested. In this study, we showed that 
PPAR activation increased the mRNA expression levels of adipocyte marker genes 
controlled by PPAR such as aP2 and LPL, whose promoters have PPRE. The findings 
suggest that PPAR as well as PPARregulates adipocyte differentiation by inducing the 
mRNA expression of adipocyte differentiation-related genes, which have PPRE in their 
promoters. 
Generally, PPAR activation enhances fatty acid oxidation in peripheral tissues such as 
the liver, heart, and skeletal muscle [21]. The enhancement of fatty acid oxidation contributes 
to the effects of PPAR activation on hyperlipidemia. Many groups including us have 
reported that treatment of a PPAR agonist suppresses weight gain of adipose tissues [22,23]. 
It has been considered that the enhancement of fatty acid oxidation is a cause of the 
suppression of adipose tissue weight gain. However, we showed here that treatment with a 
PPAR agonist decreases TG accumulation in human adipocytes. In addition to the increase 
in the mRNA expression levels of genes involved in fatty acid oxidation, the treatment with 
GW7647 significantly increased amounts of released CO2 and ASMs, which are products of 
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fatty acid oxidation, in human adipocytes. The findings indicate that PPAR activation 
enhances energy consumption in adipocytes, as well as, in hepatocytes and myocytes. It is 
unknown why only PPAR can induce fatty acid oxidation in adipocytes although PPAR 
activation, as well as, PPARactivation, can also induce adipocyte differentiation. A simple 
possibility is that the PPRE sequences of fatty-acid-oxidation-related genes show higher 
affinities to PPAR than to PPAR. Generally, a PPAR-induced response is greater than a 
PPAR-induced response in luciferase assay using an AOX-derived PPRE reporter in our 
experiments [12]. Although further investigations are necessary to elucidate the isoform 
specificity, the finding that the activation of PPAR, not PPAR, enhanced fatty acid 
oxidation in human adipocytes suggests the validity of the use of PPAR agonists for the 
management of diabetic conditions. Although PPAR agonists such as TZDs improve insulin 
resistance, long-term treatment with these agonists induces adipocyte hypertrophy causing 
severe insulin resistance [24]. However, PPAR agonists could improve insulin resistance 
without adipocyte hypertrophy, because they do not enhance the TG accumulation in 
adipocytes, as we showed here. So far, several reports have demonstrated that PPAR 
agonists improve insulin resistance in human clinical trials [8,25]. Therefore, treatment with a 
PPAR agonist is a better choice for the management of obesity-induced diabetes. 
In conclusion, we showed here that PPAR activation by GW7647 treatment increased 
the mRNA expression levels of adipocyte differentiation marker genes, GPDH activity, and 
insulin-dependent glucose uptake level in human adipocytes. However, a significant increase 
in the amount of accumulated TG was not observed under the same conditions. On the other 
hand, PPAR activation enhanced fatty acid oxidation through the induction of mRNA 
expression of genes involved in fatty acid oxidation. These findings indicate that PPAR 
activation improves insulin sensitivity without accumulation of TG, which is observed in 
PPAR agonist treatment, suggesting that PPAR agonists are valuable for improvement of 





Authors thank to Dr. C. Dani and Dr. E.Z. Amri (Universite' de Nice) for valuable 
discussion and to S. Shinotoh and Y. Tada for secretarial and technical supports, respectively. 
This work was supported by Grants-in-Aid for Scientific Research from the Ministry of 
Education, Culture, Sport, Science and Technology of Japan (22228001 and 22380075). 
 12 
References 
[1] P.J. Miranda, R.A. DeFronzo, R.M. Califf, J.R. Guyton, Metabolic syndrome: definition, 
pathophysiology, and mechanisms, Am. Heart J. 149 (2005) 33-45. 
[2] B.M. Spiegelman, J.S. Flier, Adipogenesis and obesity: rounding out the big picture. 
Cell 87 (1996) 377-389. 
[3] N. Takahashi, T. Goto, S. Hirai, T. Uemura, T. Kawada, Genome science of lipid 
metabolism and obesity, Forum Nutri. 61 (2009) 25-38. 
[4] S. Rocchi, F. Picard, J. Vamecq, et al., A unique PPAR-gamma ligand with potent 
insulin-sensitizing yet weak adipogenic activity, Mol. Cell 8 (2001) 737-747. 
[5] R.K. Semple, V.K. Chatterjee, S. O'Rahilly, PPAR-gamma and human metabolic disease, 
J. Clin. Invest. 116 (2006) 581-589. 
[6] S. Mandard, M. Müllar, S. Kersten, Peroxisome proliferator-activated receptors-alpha 
target genes, Cell. Mol. Life Sci. 61 (2004) 393-416. 
[7] A. Tsuchida, T. Yamauchi, S. Takekawa, Y. Hada, Y. Ito, T. Maki, T. Kadowaki, 
PPAR-alpha activation increases adiponectin receptors and reduces obesity-related 
inflammation in adipose tissue: comparison of activation of PPAR-alpha, PPAR-gamma, 
and their combination, Diabetes 54 (2005) 3358-3370. 
[8] A. Hiuge, A. Tenenbaum, N. Maeda, M. Benderly, M. Kumada, E.Z. Fisman, D. Tanne, 
Z. Matas, T. Hibuse, K. Fujita, H. Nishizawa, Y. Adler, M. Motro, S. Kihara, I. 
Shimomura, S. Behar, T. Funahashi, Effects of PPAR ligands, bezafibrate and 
fenofibrate, on adiponectin level, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 635-641. 
[9] C. Vernochet, S. Azoulay, D. Duval, R. Guedj, F. Cottrez, H. Vidal, G. Ailhaud, C. Dani, 
Human immunodeficiency virus protease inhibitors accumulate into cultured human 
adipocytes and alter expression of adipocytokines, J. Biol. Chem. 280 (2005) 
2238-2243. 
[10] A. M. Rodriguez, C. Elabd, F. Delteil, J. Astier, C. Vernochet, P. Saint-Marc, J. Guesnet, 
A. Guezennec, E.Z. Amri, C. Dani, G. Ailhaud, Adipocyte differentiation of multipotent 
 13 
cells established from human adipose tissue, Biochem Biophys Res Commun 315 
(2004) 255-263. 
[11] T. Uemura, T. Goto, M.S. Kang, N. Mizoguchi, S. Hirai, J.Y. Lee, Y. Nakano, J. Shono, 
S. Hoshino, K. Taketani, N. Tsuge, T. Narukami, M. Makishima, N. Takahashi, T. 
Kawada, Diosgenin, the main aglycon of fenugreek, inhibits LXR-alpha activity in 
HepG2 cells and decreases plasma and hepatic triglycerides in obese, diabetic mice, J. 
Nutr. 141 (2011) 17-23. 
[12] N. Takahashi, T. Kawada, T. Yamamoto, T. Goto, A. Taimatsu, N. Aoki, H. Kawasaki, K. 
Taira, K.K. Yokoyama, Y. Kamei, T. Fushiki, Overexpression and ribozyme-mediated 
targeting of transcriptional coactivators CBP and p300 revealed their indispensable roles 
in adipocyte differentiation through the regulation of PPAR-gamma, J. Biol. Chem. 277 
(2002) 16906-16912. 
[13] N. Takahashi, T. Kawada, T. Goto, T. Yamamoto, A. Taimatsu, N. Matsui, K. Kimura, M. 
Saito, M. Hosokawa, K. Miyashita, T. Fushiki, Dual action of isoprenols from herbal 
medicines on both PPAR-gamma and PPAR-alpha in 3T3-L1 adipocytes and HepG2 
hepatocytes, FEBS Lett. 514 (2002) 315-322. 
[14] T. Goto, N. Takahashi, S. Kato, K. Egawa, S. Ebisu, T. Moriyama, T. Fushiki, T. 
Kawada, Phytol directly activates PPAR-alpha and regulates gene expression involved 
in lipid metabolism in PPAR-alpha-expressing HepG2 hepatocytes, Biochem. Biophys. 
Res. Commun. 337 (2005) 440-445. 
[15] N. Takahashi, T. Goto, A. Taimatsu, K. Egawa, S. Kagoh, T. Kusudo, T. Sakamoto, C. 
Ohyane, JY. Lee, YI. Kim, T. Uemura, S. Hirai, T. Kawada, Bixin regulates mRNA 
expression involved in 3T3-L1 adipocytes through PPAR-gamma activation, Biochem. 
Biophys. Res. Commun. 390 (2009) 1372-1376. 
[16] T. Goto, J.Y. Lee, A. Teraminami, Y.I. Kim, S. Hirai, T. Uemura, H. Inoue, N. Takahashi, 
T. Kawada, Activation of PPAR-alpha stimulates both differentiation and fatty acid 
oxidation in adipocytes, J Lipid Res. In press. 
 14 
[17] R.M. Evans, G.D. Barish, Y.X. Wang, PPARs and complex journey to obesity, Nat. Med. 
10 (2004) 1-7. 
[18] B. Desvergne, W. Wahli, Peroxisome proliferator-activated receptors: nuclear control of 
metabolism. Endocr. Rev. 20 (1999) 649-688. 
[19] M.S. Kang, S. Hirai, T. Goto, K. Kuroyanagi, Y. Ezaki, N. Takahashi, T.
 
Kawada, 
Dehydroabietic acid, herbal terpenoid, acts as ligands for PPARs in macrophages to 
regulate inflammation, Biochem. Biophys. Res. Commun. 369 (2008) 333-338. 
[20] N. Takahashi, K.M. Kang, K. Kuroyanagi, T. Goto, S. Hirai, K. Ohyama, J.Y. Lee, R. Yu, 
M. Yano, T. Sasaki, S. Murakami, T. Kawada, Auraptene, a citrus fruit compound, 
regulates gene expression as a PPAR-alpha agonist in HepG2 hepatocytes, BioFactors 
33 (2008) 25-32. 
[21] P. Lefebvre, G. Chinetti, J.C. Fruchart, B. Staels, Sorting out the roles of PPAR-alpha in 
energy metabolism and vascular homeostasis, J. Clin. Invest. 116 (2006) 571-580. 
[22] C. Knauf, J. Rieusset, M. Foretz, P.D. Cani, M. Uldry, M. Hosokawa, E. Martinez, M. 
Bringart, A. Waget, S. Kersten, B. Desvergne, S. Gremlich, W. Wahli, J. Seydoux, N.M. 
Delzenne, B. Thorens, R. Burcelin, PPAR-alpha-null mice have increased white adipose 
tissue glucose utilization, GLUT4, and fat mass: Role in liver and brain, Endocrinol. 
147 (2006) 4067-4078. 
[23] M.S.Kang, S. Hirai, T. Goto, K. Kuroyanagi, I.Y. Kim, K. Ohyama, T. Uemura, J.Y. Lee, 
T. Sakamoto, Y. Ezaki, R. Yu, N. Takahashi, T. Kawada, Dehydroabietic acid, a 
phytochemical, acts as ligand for PPARs in macrophages and adipocytes to regulate 
inflammation of mouse adipose tissues. BioFactors 35 (2009) 442-448. 
[24] C. Fernandes-Santos, R.E. Carneiro, L. de-Souza-Mendonca, M.B. Aguila, C.A. 
Mandarim-de-Lacerda, Pan-PPAR agonist beneficial effects in overweight mice fed a 
high-fat high-sucrose diet, Nutrition 25 (2009) 818-827. 
[25] S. Ogawa, K. Takeuchi, K. Sugimura, M. Fukuda, R. Lee, S. Ito, T. Sato, Bezafibrate 
reduces blood glucose in type-2 diabetes mellitus, Metabol. 49 (2000) 331-334. 
 15 
Figure legends 
Fig. 1. Effects of PPAR agonist (GW7647) on differentiation of human adipocytes. (A) 
mRNA expression levels of adipocyte differentiation marker genes (PPAR, aP2, and LPL) in 
human adipocytes incubated with 100 nM GW7647 for 12 days. The value of a vehicle 
control was set at 100% and relative value is presented as fold induction with respect to that 
of each vehicle control. The values are means ±S.E.M. of 3-4 samples. *P<0.05 compared 
with each vehicle control. (B) GPDH activity in GW7647-treated human adipocytes. *P<0.05 
and **P<0.01 compared with each vehicle control. 
 
Fig. 2. Effects of GW7647 on insulin sensitivity. Insulin-dependent glucose uptake into 
human adipocytes incubated with GW7647 for 12 days. The value of a vehicle control was set 
at 100% and the relative value is presented as fold induction with respect to that of the vehicle 
control. The values are means ±S.E.M. of 3-4 samples. *P<0.05 and **P<0.01 compared with 
vehicle controls. 
 
Fig. 3. Effects of GW7647 on lipid accumulation. (A) Oil Red O staining of a vehicle 
control and GW7647-treated human adipocytes 12 days after differentiation induction. Scale 
bars indicate 200 M. (B) TG amounts in the GW7647-treated human adipocytes. The value 
of a vehicle control was set at 100% and the relative value is presented as fold induction with 
respect to that of the vehicle control. Total TG amount in each well is calculated using 
concentrations of lipid-extracted solutions. The values are means ±S.E.M. of 3-4 samples. 
 
Fig. 4. Effects of GW7647 on fatty acid oxidation. (A) mRNA expression levels of 
adipocyte differentiation marker genes (CPT-1B, AOX, and UCP1) in human adipocytes 
incubated with 100 nM GW7647 for 12 days. (B) Effects of GW6471 (a PPAR antagonist) 
on the induction of CPT-1B mRNA expression. GW7647 and GW6471 (an agonist and 
antagonist, respectively) were added to the culture, which was then incubated for 12 days. (C) 
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CO2 release and (D) acid-soluble metabolite (ASM) release in GW7647-treated human 
adipocytes. The value of a vehicle control was set at 100% and the relative value was 
presented as fold induction with respect to that of the vehicle control. The values are means 
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